[fam-] trastuzumab deruxtecan (DS-8201) - Daiichi Sankyo
DS-8201: Approval and launch in US/EU/Japan/Asia for HER2 positive breast cancer in FY 2020 (Daiichi Sankyo) - Apr 26, 2019 - FY 2018 Results 
BLA • European regulatory • Japanese regulatory • Launch Europe • Launch Japan • Launch non-US • Launch US • Non-US regulatory
https://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005441/FY2018%20Q4%20Reference%20Data%20(Corrected%20Version).pdf
 
Apr 26, 2019
 
 
1850ddbc-d9dc-4566-9bee-ca3b6e4adbd9.jpg